SP1 and diabetic kidney disease: Mechanistically, as summarized in Fig. 7, in DKD, hyperglycemia activates the HBP to promote or inhibit SP1 O-glycosylation via a negative feedback mechanism, thus regulating ENTPD5 expression at the transcriptional level.